Foghorn Therapeutics, Inc. (FHTX)
1.88
+0.03
(+1.62%)
USD |
NASDAQ |
Oct 19, 15:47
Foghorn Therapeutics Net Income (Quarterly) : -7.191M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.191M |
| March 31, 2026 | -19.88M |
| December 31, 2025 | -21.66M |
| September 30, 2025 | -15.85M |
| June 30, 2025 | -17.94M |
| March 31, 2025 | -18.83M |
| December 31, 2024 | -19.50M |
| September 30, 2024 | -19.12M |
| June 30, 2024 | -22.98M |
| March 31, 2024 | -25.02M |
| December 31, 2023 | -24.11M |
| September 30, 2023 | -14.34M |
| June 30, 2023 | -29.49M |
| Date | Value |
|---|---|
| March 31, 2023 | -30.49M |
| December 31, 2022 | -28.89M |
| September 30, 2022 | -25.77M |
| June 30, 2022 | -27.31M |
| March 31, 2022 | -26.91M |
| December 31, 2021 | -29.14M |
| September 30, 2021 | -26.08M |
| June 30, 2021 | -23.11M |
| March 31, 2021 | -22.99M |
| December 31, 2020 | -20.76M |
| September 30, 2020 | -18.37M |
| June 30, 2020 | -15.72M |
| March 31, 2020 | -13.95M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 16.07M |
| Total Expenses (Quarterly) | 23.26M |
| EPS Diluted (Quarterly) | -0.1018 |
| Enterprise Value | -15.86M |
| Gross Profit Margin (Quarterly) | 98.76% |
| Profit Margin (Quarterly) | -44.74% |
| Earnings Yield | -54.33% |
| Normalized Earnings Yield | -50.45 |